Search

Your search keyword '"Schoettker, Bjoern"' showing total 8 results
Start Over Author "Schoettker, Bjoern"
8 results on '"Schoettker, Bjoern"'

1. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Author

Fürstenau, Moritz, Thus, Yvonne J., Robrecht, Sandra, Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie, von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjoern, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Nösslinger, Thomas, Baumann, Michael, Hebart, Holger, Gaska, Tobias, Regelink, Josien C., Dompeling, Ellen C., Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Spaargaren, Marcel, Eldering, Eric, Stilgenbauer, Stephan, Niemann, Carsten U., Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Published
2023
Full Text
View/download PDF

2. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Author

Eichhorst, Barbara, Niemann, Carsten U., Kater, Arnon P., Fuerstenau, Moritz, von Tresckow, Julia, Zhang, Can, Robrecht, Sandra, Gregor, Michael, Juliusson, Gunnar, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Lindstrom, Vesa, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian B., Illmer, Thomas, Schoettker, Bjoern, Noesslinger, Thomas, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Frederiksen, Henrik, van der Klift, Marjolein, Jaeger, Ulrich, Leys, Maria B. L., Hoogendoorn, Mels, Lotfi, Kourosh, Hebart, Holger, Gaska, Tobias, Koene, Harry, Enggaard, Lisbeth, Goede, Jereon, Regelink, Josien C., Widmer, Anouk, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl A., Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Levin, Mark-David, van Oers, Marinus, Geisler, Christian, Stilgenbauer, Stephan, Hallek, Michael, Eichhorst, Barbara, Niemann, Carsten U., Kater, Arnon P., Fuerstenau, Moritz, von Tresckow, Julia, Zhang, Can, Robrecht, Sandra, Gregor, Michael, Juliusson, Gunnar, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Lindstrom, Vesa, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian B., Illmer, Thomas, Schoettker, Bjoern, Noesslinger, Thomas, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Frederiksen, Henrik, van der Klift, Marjolein, Jaeger, Ulrich, Leys, Maria B. L., Hoogendoorn, Mels, Lotfi, Kourosh, Hebart, Holger, Gaska, Tobias, Koene, Harry, Enggaard, Lisbeth, Goede, Jereon, Regelink, Josien C., Widmer, Anouk, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl A., Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Levin, Mark-David, van Oers, Marinus, Geisler, Christian, Stilgenbauer, Stephan, and Hallek, Michael

Abstract

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Methods In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) or 12 cycles of venetoclax-rituximab, venetoclax-obinutuzumab, or venetoclax-obinutuzumab-ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity, <10(-4) [i.e., <1 CLL cell in 10,000 leukocytes]) as assessed by flow cytometry in peripheral blood at month 15 and progression-free survival. Results A total of 926 patients were assigned to one of the four treatment regimens (229 to chemoimmunotherapy, 237 to venetoclax-rituximab, 229 to venetoclax-obinutuzumab, and 231 to venetoclax-obinutuzumab-ibrutinib). At month 15, the percentage of patients with undetectable minimal residual disease was significantly higher in the venetoclax-obinutuzumab group (86.5%; 97.5% confidence interval [CI], 80.6 to 91.1) and the venetoclax-obinutuzumab-ibrutinib group (92.2%; 97.5% CI, 87.3 to 95.7) than in the chemoimmunotherapy group (52.0%; 97.5% CI, 44.4 to 59.5; P<0.001 for both comparisons), but it was not significantly higher in the venetoclax-rituximab group (57.0%; 97.5% CI, 49.5 to 64.2; P=0.32). Three-year progression-free survival was 90.5% in the venetoclax-obinutuzumab-ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ratio for disease progression or death, 0.32; 97.5% CI, 0.19 to 0.54; P<0.001). Progression-free survival at 3 years was also higher with venetoclax-obinutuzumab (87.7%; hazard ratio for, Funding Agencies|AbbVie

Published
2023
Full Text
View/download PDF

3. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M.N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Published
2022
Full Text
View/download PDF

4. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Author

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan

Published
2022
Full Text
View/download PDF

5. COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Author

Fuerstenau, Moritz, Langerbeins, Petra, De Silva, Nisha, Fink, Anna Maria, Robrecht, Sandra, von Tresckow, Julia, Simon, Florian, Hohloch, Karin, Droogendijk, Jolanda, van der Klift, Marjolein, van der Spek, Ellen, Illmer, Thomas, Schoettker, Bjoern, Fischer, Kirsten, Wendtner, Clemens M., Tausch, Eugen, Stilgenbauer, Stephan, Niemann, Carsten U., Gregor, Michael, Kater, Arnon P., Hallek, Michael, Eichhorst, Barbara, Fuerstenau, Moritz, Langerbeins, Petra, De Silva, Nisha, Fink, Anna Maria, Robrecht, Sandra, von Tresckow, Julia, Simon, Florian, Hohloch, Karin, Droogendijk, Jolanda, van der Klift, Marjolein, van der Spek, Ellen, Illmer, Thomas, Schoettker, Bjoern, Fischer, Kirsten, Wendtner, Clemens M., Tausch, Eugen, Stilgenbauer, Stephan, Niemann, Carsten U., Gregor, Michael, Kater, Arnon P., Hallek, Michael, and Eichhorst, Barbara

Published
2020

8. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.

Author

Scheppach W, Reissmann N, Sprinz T, Schippers E, Schoettker B, and Mueller JG

Subjects
Biopsy, Chemotherapy, Adjuvant, Colectomy, Colonic Neoplasms pathology, Colonic Neoplasms surgery, Colonoscopy, Doxorubicin administration & dosage, Fatal Outcome, Hepatectomy, Humans, Ifosfamide administration & dosage, Liver Neoplasms secondary, Liver Neoplasms surgery, Magnetic Resonance Imaging, Male, Pelvic Neoplasms secondary, Pelvic Neoplasms surgery, Perivascular Epithelioid Cell Neoplasms secondary, Perivascular Epithelioid Cell Neoplasms surgery, Predictive Value of Tests, Reoperation, Time Factors, Treatment Outcome, Young Adult, Antibiotics, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colonic Neoplasms drug therapy, Drug Resistance, Neoplasm, Liver Neoplasms drug therapy, Pelvic Neoplasms drug therapy, Perivascular Epithelioid Cell Neoplasms drug therapy, Sirolimus therapeutic use
Abstract

A 23-year-old male presented with a three-week-history of crampy abdominal pain and melaena. Colonoscopy revealed a friable mass filling the entire lumen of the cecum; histologically, it was classified as perivascular epithelioid cell tumor (PEComa). An magnetic resonance imaging scan showed, in addition to the primary tumor, two large mesenteric lymph node metastases and four metastatic lesions in the liver. The patient underwent right hemicolectomy and left hemihepatectomy combined with wedge resections of metastases in the right lobe of the liver, the resection status was R0. Subsequently, the patient was treated with sirolimus. After 4 mo of adjuvant mammalian target of rapamycin inhibition he developed two new liver metastases and a local pelvic recurrence. The visible tumor formations were again excised surgically, this time the resection status was R2 with regard to the pelvic recurrence. The patient was treated with 12 cycles of doxorubicin and ifosfamide under which the disease was stable for 9 mo. The clinical course was then determined by rapid tumor growth in the pelvic cavity. Second line chemotherapy with gemcitabine and docetaxel was ineffective, and the patient died 23 mo after the onset of disease. This case report adds evidence that, in malignant PEComa, the mainstay of treatment is curative surgery. If not achievable, the effects of adjuvant or palliative chemotherapy are unpredictable.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results